Navigation Links
C8 MediSensors Closes $19 million Preferred Stock Financing
Date:6/11/2012

SAN JOSE, Calif., June 11, 2012 /PRNewswire/ -- C8 MediSensors, Inc. (www.c8medisensors.com), the leading company developing noninvasive continuous glucose monitoring for people with diabetes, announced today that it has raised an incremental $19 million through the sale of Preferred C-1 stock.

(Logo:  http://photos.prnewswire.com/prnh/20120406/AQ83655LOGO)

This additional round of funding helps C8 MediSensors prepare for its upcoming product launch in Europe. C8 MediSensors' leading investors participated in this funding round.

Nearly 300 million people worldwide suffer from diabetes. C8 MediSensors has pioneered the use of light, specifically Raman spectroscopy, to measure glucose non-invasively with a continuous glucose monitor that is worn around the abdomen and sends readings to the user's smartphone. 

C8 MediSensors' CEO, Paul Zygielbaum, himself a person with diabetes, commented: "Better diabetes management requires better glucose visibility to the patient. You can't control what you can't see. After years of research, development and clinical testing, we are thrilled to be on the verge of introducing our optical glucose monitor, which is designed to provide people like me with continuous visibility into their glucose levels throughout the day."

C8 MediSensors has filed for CE Mark approval and plans to introduce their optical continuous glucose monitor in Europe in 2H 2012, pending regulatory approval.

About C8 MediSensors

Headquartered in San Jose CA, C8 MediSensors' breakthrough patent-protected technology is being developed to give people with diabetes an adjunctive, continuous view of their glucose levels.
Visit www.c8medisensors.com.

This document contains forward-looking statements. Any statements contained in this document that are not statements of historical fact may be deemed to be forward- looking statements, including, without limitation, statements relating to C8 MediSensors' anticipated product sales and financing needs. These forward-looking statements are based upon C8 MediSensors' current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with market conditions, customer demand for the product, and risks and uncertainties associated with C8 MediSensors' business and finances in general. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. C8 MediSensors does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

C8 MediSensors, Inc. 6375 San Ignacio Avenue, San Jose, CA 95119, USA

www.C8MediSensors.com


'/>"/>
SOURCE C8 MediSensors, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Closes Cameron Health Acquisition
2. Stereotaxis Closes $18.5 Million Private Placement Financings
3. Independa Closes Convertible Note Funding at $2.35 Million
4. Novelos Therapeutics Prices $5.4 Million Public Offering
5. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
6. InnoPharma Inc. Raises $8 Million in Venture Debt
7. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
8. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
9. AssureRx Health Raises $12.5 Million Series C Financing
10. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
11. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Wash. , Jan. 16, 2017  Verathon ® Inc., ... announced the launch of new GlideScope ® Spectrum TM ... Dynamic Light Control TM and Ambient Light Reduction TM ... Continue Reading ... ...
(Date:1/16/2017)... When synthetic Fentanyl arrived on the streets in 2015, dealers ... free samples, inviting would-be customers to test a newly-created batch. ... The rapidly-growing demand for the ... morphine, has racked up a staggering death toll across ... recorded fentanyl sales reveals that they have sold nearly 400 ...
(Date:1/16/2017)... Jan. 16, 2017  Northern Colorado,s newest tattoo removal ... laser treatments to Loveland featuring ... on the removal of unwanted tattoos and delivers complete ... cover-ups. "Tattoos are beautiful forms of self-expression, ... hope they would," said Johnny Trzasko , owner. ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... ... announced the addition of Victor Giamos, MD to their medical staff, according to ... Partner at North Shore Eye Care, a division of SightMD. Dr. Giamos will ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... ... ... are well-aware of the following facts at present:, Flu and ... no effect on keeping this particularly bad strain of the flu away , ... sniffling , These facts are well-known among the team at Woodard! About ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon ... , the official journal of The American Society for Aesthetic Plastic Surgery, in ... procedure is designed to correct drooping, retracted lower eyelids, which usually result from ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all ... but to test for, as well. The money spent screening for and treating cancer ... the U.S. screen patients for cancer more than in any other country that has ...
Breaking Medicine News(10 mins):